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As NASA and other space agencies prepare for future long-term space missions beyond 
the LEO, the cumulative impact of risk factors encountered in space increases 
substantially rising concerns about astronauts health. Application of on-board 
medications to mitigate clinical symptoms associated with certain medical conditions and 
illnesses is the first line of response to ensure sustainable health and performance of 
crew.Unfortunately, very limited research has been conducted to determine efficacy of 
the earth-based pharmaceuticals in a microgravity environment. In some instances, orally 
administered medications taken during flight were reported to be less effective than 
expected. 
Evaluation of series of experiments involving astronauts from shuttle flights shows 
notable individual variability to several pharmaceuticals during flight. These data provide 
reasonable assumption of perturbation in CYP450 enzymes during spaceflight, which 
contribute to the hepatic metabolism of the majority of drugs and therefore may have 
significant effects on therapeutic efficacy and increase treatment-related toxicity.The 
genes encoding the CYP450 enzymes are highly variable in humans. Inheritable 
variations of CYP450 hepatic metabolizer enzymes and transport proteins play a crucial 
role in the inter-individual variability of drug efficiency and risks of adverse drug 
reactions. Additionally, there are some reports that document changes in the levels of 
production of drug-metabolizing enzymes in microgravity. Therefore, in order to provide 
a safe and effective pharmaceutical treatment in space, medications selection should be 
based not only on the specific efficacy of medications but also on the individual drug 
sensitivity and flight-induced changes in metabolism of astronauts chosen for a particular 
mission. To our knowledge, there was no pre-flight drug sensitivity testing on a genetic 
level for any of the previous manned NASA space missions. Therefore, technologies 
capable of predicting and managing medication efficacy, side effects, and toxicity of 
drugs based on individual genetic variability of crew members are increasingly needed. 
In this report, we present results of testing the market available Personalized Prescribing 
System (PPS), a comprehensive, non-invasive solution for safer, targeted medication 
management for every crew member. Statistical accuracy and simplicity of non-invasive 
sample analysis demonstrate the feasibility of drug sensitivity assessment and record-
keeping tool for flight surgeons and astronauts in applying the recommended medications 
for situations arising in flight. The information on individual drug sensitivity will 
translate into personalized risk assessment for adverse drug reactions and treatment 
failures for each drug from the medication kit as well as predefined outcome. This will 
address the HHC’s raised “Concern of Clinically Relevant Unpredicted Effects of 
Medication” as recently updated. 
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